Automate Your Wheel Strategy on BIIB
With Tiblio's Option Bot, you can configure your own wheel strategy including BIIB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIIB
- Rev/Share 68.1173
- Book/Share 124.1985
- PB 1.4232
- Debt/Equity 0.3619
- CurrentRatio 2.7163
- ROIC 0.0796
- MktCap 25931093599.0
- FreeCF/Share 15.5348
- PFCF 11.3863
- PE 16.1101
- Debt/Assets 0.2256
- DivYield 0
- ROE 0.0925
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BIIB | UBS | -- | Neutral | -- | $185 | Jan. 7, 2026 |
| Downgrade | BIIB | HSBC Securities | Hold | Reduce | -- | $143 | Dec. 10, 2025 |
| Upgrade | BIIB | Stifel | Hold | Buy | -- | $202 | Nov. 6, 2025 |
| Initiation | BIIB | Jefferies | -- | Buy | -- | $190 | Sept. 25, 2025 |
| Resumed | BIIB | Truist | -- | Hold | -- | $142 | July 21, 2025 |
| Downgrade | BIIB | HSBC Securities | Buy | Hold | -- | $118 | April 28, 2025 |
| Downgrade | BIIB | Argus | Buy | Hold | -- | -- | April 4, 2025 |
| Initiation | BIIB | Bernstein | -- | Market Perform | -- | $160 | Feb. 11, 2025 |
| Downgrade | BIIB | Piper Sandler | Overweight | Neutral | $315 | $138 | Jan. 2, 2025 |
| Downgrade | BIIB | BMO Capital Markets | Outperform | Market Perform | $230 | $164 | Dec. 20, 2024 |
News
These Are The Worst 25 Stocks to Own in February
Published: February 03, 2026 by: Schaeffers Research
Sentiment: Negative
It's been an interesting start to the year, with plenty of geopolitical developments for investors to unpack.
Read More
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
Biogen heads into Q4 earnings with MS drug pressure, while Leqembi and Skyclarys' growth could help offset declines ahead of its Feb. 6 report.
Read More
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Negative
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
BIIB secures FDA's Breakthrough Therapy status for litifilimab in cutaneous lupus, backed by phase II results, while advancing phase III and broader lupus studies.
Read More
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Published: January 12, 2026 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease and represents approximately 95% of all SMA cases.2 The SPINRAZA European Union marketing authorization has been updated to include the high dose regimen. The new high dose regimen comprises a more rapid loading phase, two 50 mg loading doses …
Read More
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Published: December 30, 2025 by: Seeking Alpha
Sentiment: Positive
Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, as a driver of Biogen's EBIT growth. Its sales totaled $132.9 million in Q3, up 29.9% year-over-year.
Read More
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with over 3.5 years of follow-up. These results show that early initiation of QALSODY was associated with numerically slower decline in measures of clinical function, breathing and strength, as well as reduction in the risk of death or permanent ventilation. Sustained reductions in …
Read More
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Published: December 05, 2025 by: Business Wire
Sentiment: Neutral
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced data presentations that further support the potential of zorevunersen, an investigational antisense oligonucleotide, as a disease-modifying medicine for Dravet syndrome. These data were presented at the 2025 American Epilepsy Society (AES).
Read More
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Published: December 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life—
Read More
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (BIIB) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Biogen shares could climb on Leqembi uptake – Jefferies
Published: November 28, 2025 by: Proactive Investors
Sentiment: Positive
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) could see its stock move higher over the next two years as progress on its Alzheimer's drug Leqembi and a series of late-stage pipeline readouts draw more investor attention, according to Jefferies. The broker, which rates the stock Buy with a price target of $210, said Leqembi's trajectory in early Alzheimer's disease “could accelerate” if a subcutaneous induction version wins approval in mid-2026, enabling full at-home use.
Read More
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
Read More
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
Read More
Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease
Published: October 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have confirmed amyloid pathology
Read More
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Read More
Can Biogen Stock Rebound as New Drugs Aim to Offset MS Sales Declines?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Biogen's new drugs Leqembi, Skyclarys and Zurzuvae are driving fresh momentum, but MS and Spinraza declines cloud its growth path.
Read More
Biogen's Comeback: Why The Bulls Are Finally Winning Again
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Positive
Mr. Market's bullish sentiment towards Biogen is returning. One reason for this is its strengthening position in the multiple sclerosis drugs market, thanks to Vumerity, whose sales reached $212.3 million in Q2 2025, up 28% year-on-year. Also, Biogen's EBIT margin has continued to grow over the past four quarters, reaching 34.6% for the three months ended June 30, 2025.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
BIIB Stock: Is Biogen Still A Buy After The 14% Spike?
Published: October 03, 2025 by: Forbes
Sentiment: Positive
Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company's market value has increased by approximately $3.3 billion over the past 5 days, bringing its current market capitalization to around $23 billion.
Read More
Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (NASDAQ:BIIB ) Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDT Company Participants Priya Singhal - Executive VP & Head of Development Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Read More
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.
Read More
Biogen Gets EU Nod for First Postpartum Depression Drug
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
BIIB secures EU approval for Zurzuvae, the first oral treatment for postpartum depression, boosting its long-term growth prospects.
Read More
Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.
Read More
FDA recommends more monitoring of Alzheimer's patients on Biogen's drug Leqembi
Published: August 28, 2025 by: Reuters
Sentiment: Negative
The U.S. Food and Drug Administration said on Thursday it is recommending an additional, earlier magnetic resonance imaging monitoring prior to the third infusion for patients with Alzheimer's disease taking Biogen's drug Leqembi.
Read More
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period –
Read More
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
Published: August 11, 2025 by: Business Wire
Sentiment: Neutral
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced that the first patient has been dosed in the global Phase 3 EMPEROR study of zorevunersen for the treatment of Dravet syndrome. Zorevunersen, an investigational antisense oligonucleotide, has the potential to be the first disease-modifyi.
Read More
Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (NASDAQ:BIIB ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Alisha A. Alaimo - President & Head of North America Christopher A.
Read More
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Read More
About Biogen Inc. (BIIB)
- IPO Date 1991-09-17
- Website https://www.biogen.com
- Industry Drug Manufacturers - General
- CEO Christopher A. Viehbacher
- Employees 7605